J&J Q3 Sales $25.40B, Adjusted EPS $2.59; Lifts Full-Year EPS Guidance

The headline beat on adjusted EPS and the midpoint of sales guidance sits essentially in line with consensus, so the raised EPS floor is the more meaningful signal — management is expressing confidence in margins even as the top line tracks expectations. The negative premarket reaction suggests the market had positioned for more, which is the recurring pattern when a defensive healthcare name merely meets revenue. What matters next is whether the sales range holds at the upper end and whether the earnings revision reflects durable operating leverage or one-off items; that distinction will determine if the guidance raise is treated as a floor or a ceiling.